Complete Response to Nivolumab‐Relatlimab Following Progression of Invasive Sinonasal Mucosal Melanoma on First‐Line Nivolumab‐Ipilimumab: A Case Report

ABSTRACT Background Mucosal melanoma (MM) is a rare and aggressive subtype of melanoma with a notably worse prognosis than cutaneous melanoma (CM) due to its occult presentation and unique molecular profile. For advanced cases, immunotherapy has improved outcomes in recent years, although more signi...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Reema Patel, Louisa Post‐Zwicker, Varinder Kaur
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Wiley 2026-04-01
Edice:	Cancer Reports
Témata:	immunotherapy mucosal melanoma relatlimab
On-line přístup:	https://doi.org/10.1002/cnr2.70544
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!